Pure Global AI
NCT06382116Not yet recruiting

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Platinum Based Chemotherapy (First-line of Systemic Treatment) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After EGFR-TKI Failure
Sichuan Baili Pharmaceutical Co., Ltd.Phase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
BL-B01D1
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Location
Guangzhou, China
Timeline & enrollment
Phase
Phase 3
Start date
May 01, 2024
End date
May 01, 2026
Enrollment
428 participants
Primary outcome

Progression-free survival (PFS)

Summary

This trial is a registered phase III, randomized, open-label, multicenter study to evaluate
 the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic
 non-squamous non-small cell lung cancer with EGFR-sensitive mutations after EGFR-TKI failure.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06382116
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06382116 through Pure Global AI's free database. This Phase 3 trial is sponsored by Sichuan Baili Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 428 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.